Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis

British Journal of Pharmacology

Volumn 166, Issue 3, 2012, Pages 1183-1191

  Toyama, K ^a   Yonezawa, A ^a   Masuda, S ^a   Osawa, R ^a   Hosokawa, M ^b   Fujimoto, S ^b   Inagaki, N ^b   Inui, K ^a,c   Katsura, T ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

genetic variant; H + organic cation antiporter; kidney; liver; toxicodynamics

Indexed keywords

BICARBONATE; DRINKING WATER; LACTIC ACID; METFORMIN; MULTIDRUG AND TOXIN EXTRUSION 1 PROTEIN; ORGANIC CATION TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BICARBONATE BLOOD LEVEL; BLOOD PH; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ACCUMULATION; DRUG LIVER LEVEL; GENE FUNCTION; GENE INACTIVATION; GENE LOSS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; MALE; MOLECULAR PATHOLOGY; MORNING DOSAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; TREATMENT DURATION; WILD TYPE;

ACIDOSIS, LACTIC; ANIMALS; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HOMOZYGOTE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; KIDNEY FUNCTION TESTS; LACTIC ACID; LIVER; LIVER FUNCTION TESTS; METFORMIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGANIC CATION TRANSPORT PROTEINS; SPECIES SPECIFICITY; TRANSFECTION;

EID: 84860865479     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01853.x     Document Type: Article

References (28)

1. Bailey CJ, Turner RC, (1996). Metformin. N Engl J Med 334: 574-579.
2. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH, (2009). Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 58: 745-749.
3. Chen L, Pawlikowski B, Schlessinger A, More SS, Stryke D, Johns SJ, et al,. (2010). Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics 20: 687-699.
4. Chen Y, Teranishi K, Li S, Yee SW, Hesselson S, Stryke D, et al,. (2009). Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J 9: 127-136.
5. Ito S, Kusuhara H, Kuroiwa Y, Wu C, Moriyama Y, Inoue K, et al,. (2010). Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 333: 341-350.
6. al-Jebawi AF, Lassman MN, Abourizk NN, (1998). Lactic acidosis with therapeutic metformin blood level in a low-risk diabetic patient. Diabetes Care 21: 1364-1365.
7. Kajiwara M, Terada T, Ogasawara K, Iwano J, Katsura T, Fukatsu A, et al,. (2009). Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. J Hum Genet 54: 40-46.
8. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, et al,. (2005). Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20: 379-386.
9. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, et al,. (2011). Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 89: 837-844.
10. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al,. (2008). SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359: 789-799.
11. +/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 17: 2127-2135.
12. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB, (2010). Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol 298: F997-F1005.
13. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA, (1998). Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 338: 265-266.
14. Mizuno T, Terada T, Kamba T, Fukudo M, Katsura T, Nakamura E, et al,. (2010). ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann Oncol 21: 1382-1383.
15. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y, (2005). A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A 102: 17923-17928.
16. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M, (2006). SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16: 873-879.
17. Pearlman BL, Fenves AZ, Emmett M, (1996). Metformin-associated lactic acidosis. Am J Med 101: 109-110.
18. Safadi R, Dranitzki-Elhalel M, Popovtzer M, Ben-Yehuda A, (1996). Metformin-induced lactic acidosis associated with acute renal failure. Am J Nephrol 16: 520-522.
19. Scheen AJ, (1996). Clinical pharmacokinetics of metformin. Clin Pharmacokinet 30: 359-371.
20. Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB, (2004). Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 255: 179-187.
21. +-organic cation antiporters. Biochem Pharmacol 74: 359-371.
22. Toyama K, Yonezawa A, Tsuda M, Masuda S, Yano I, Terada T, et al,. (2010). Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. Pharmacogenet Genomics 20: 135-138.
23. Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, Inui K, (2009). Targeted disruption of the multidrug and toxin extrusion 1 (Mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol 75: 1280-1286.
24. Tymms DJ, Leatherdale BA, (1988). Lactic acidosis due to metformin therapy in a low risk patient. Postgrad Med J 64: 230-231.
25. Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y, (2003). Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 63: 844-848.
26. Yonezawa A, Inui K, (2011). Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/ toxicodynamics and pharmacogenomics. Br J Pharmacol 164: 1817-1825.
27. Young ME, Radda GK, Leighton B, (1996). Activation of glycogen phosphorylase and glycogenolysis in rat skeletal muscle by AICAR-an activator of AMP-activated protein kinase. FEBS Lett 382: 43-47.
28. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al,. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174.